![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
RF Kauffman, VG Crowe, BG Utterback and DW Robertson
LY195115 selectively inhibited the peak III isozyme of cardiac cyclic nucleotide phosphodiesterase (PDE) eluted from DEAE-cellulose columns. Inhibition curves were biphasic, suggesting heterogeneity within this preparation. Since peak III PDE is reported to be derived from membranes, effects of LY195115 upon PDE associated with cardiac membranes were examined. LY195115-sensitive PDE measured in the various membrane fractions correlated well with the sarcoplasmic reticulum marker Ca2+-ATPase (r = 0.94; p less than 0.001), but not with Na+,K+- ATPase or azide-sensitive ATPase. Membrane disruption failed to reveal latent LY195115-sensitive PDE in sarcolemmal vesicles known to be primarily right side out. The results suggest that LY195115-sensitive PDE is located within sarcoplasmic reticulum membranes with a distribution similar or identical to that of Ca2+-ATPase. Accordingly, LY195115-sensitive PDE was referred to as SR-PDE. A subfraction of sarcoplasmic reticulum vesicles (free SR vesicles) was sufficiently homogeneous with respect to SR-PDE activity to carry out steady state kinetic studies. Double reciprocal plots of cAMP hydrolysis were linear, yielding Km and Vmax values of 0.46 +/- 0.03 microM and 700 +/- 90 pmol/min/mg of vesicle protein, respectively. LY195115 was a linear competitive inhibitor of SR-PDE with a Ki of 80 +/- 10 nM. -LogIC50 values for inhibition of SR-PDE by a series of structural analogues of LY195115 correlated highly with published -logED50 values for stimulation of cardiac contractility in vivo (r = 0.91, p less than 0.001). Consequently, in vivo effects of LY195115 upon the heart appear to result primarily from competitive inhibition of SR-PDE, or from binding to a site with a topography similar or identical to that of the catalytic site of SR-PDE.
This article has been cited by other articles:
|
|
 |
|
  B.-G. Kerfant, D. Zhao, I. Lorenzen-Schmidt, L. S. Wilson, S. Cai, S. R. W. Chen, D. H. Maurice, and P. H. Backx PI3K{gamma} Is Required for PDE4, not PDE3, Activity in Subcellular Microdomains Containing the Sarcoplasmic Reticular Calcium ATPase in Cardiomyocytes Circ. Res., August 17, 2007; 101(4): 400 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Yan, C. L. Miller, and J.-i. Abe Regulation of Phosphodiesterase 3 and Inducible cAMP Early Repressor in the Heart Circ. Res., March 2, 2007; 100(4): 489 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fischmeister, L. R.V. Castro, A. Abi-Gerges, F. Rochais, J. Jurevicius, J. Leroy, and G. Vandecasteele Compartmentation of Cyclic Nucleotide Signaling in the Heart: The Role of Cyclic Nucleotide Phosphodiesterases Circ. Res., October 13, 2006; 99(8): 816 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Xiang, F. Naro, M. Zoudilova, S.-L. C. Jin, M. Conti, and B. Kobilka Phosphodiesterase 4D is required for {beta}2 adrenoceptor subtype-specific signaling in cardiac myocytes PNAS, January 18, 2005; 102(3): 909 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yano, M. Kohno, T. Ohkusa, M. Mochizuki, J. Yamada, M. Kohno, T. Hisaoka, K. Ono, T. Tanigawa, S. Kobayashi, et al. Effect of milrinone on left ventricular relaxation and Ca2+ uptake function of cardiac sarcoplasmic reticulum Am J Physiol Heart Circ Physiol, October 1, 2000; 279(4): H1898 - H1905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kenan, T. Murata, Y. Shakur, E. Degerman, and V. C. Manganiello Functions of the N-terminal Region of Cyclic Nucleotide Phosphodiesterase 3 (PDE 3) Isoforms J. Biol. Chem., April 14, 2000; 275(16): 12331 - 12338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tanigawa, M. Yano, M. Kohno, T. Yamamoto, T. Hisaoka, K. Ono, T. Ueyama, S. Kobayashi, Y. Hisamatsu, T. Ohkusa, et al. Mechanism of preserved positive lusitropy by cAMP-dependent drugs in heart failure Am J Physiol Heart Circ Physiol, February 1, 2000; 278(2): H313 - H320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Toyonaga, T. Nakatsu, T. Murakami, S. Kusachi, K. Mashima, Y. Tominaga, S. Yamane, T. Uesugi, H. Kanai, and T. Tsuji Effects of Cilostazol on Heart Rate and its Variation in Patients With Atrial Fibrillation Associated With Bradycardia Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(3): 183 - 191. [Abstract] [PDF]
|
|
|
|
 |
|
 C. J. Smith, R. Huang, D. Sun, S. Ricketts, C. Hoegler, J.-Z. Ding, R. A. Moggio, and T. H. Hintze Development of Decompensated Dilated Cardiomyopathy Is Associated With Decreased Gene Expression and Activity of the Milrinone-Sensitive cAMP Phosphodiesterase PDE3A Circulation, November 4, 1997; 96(9): 3116 - 3123. [Abstract] [Full Text]
|
|
|
|
|
|
R. Draijer, D. E. Atsma, A. van der Laarse, and V. W.M. van Hinsbergh cGMP and Nitric Oxide Modulate Thrombin-Induced Endothelial Permeability : Regulation via Different Pathways in Human Aortic and Umbilical Vein Endothelial Cells Circ. Res., February 1, 1995; 76(2): 199 - 208. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Shakur, K. Takeda, Y. Kenan, Z.-X. Yu, G. Rena, D. Brandt, M. D. Houslay, E. Degerman, V. J. Ferrans, and V. C. Manganiello Membrane Localization of Cyclic Nucleotide Phosphodiesterase 3 (PDE3). TWO N-TERMINAL DOMAINS ARE REQUIRED FOR THE EFFICIENT TARGETING TO, AND ASSOCIATION OF, PDE3 WITH ENDOPLASMIC RETICULUM J. Biol. Chem., December 1, 2000; 275(49): 38749 - 38761. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
